NJ Bio

NJ Bio, Inc. an affiliate of Cohance Lifesciences, is a U.S.-based CRO/CDMO specializing in integrated chemistry, biology, and translational services for ADCs and other complex bioconjugates. NJ Bio’s deep scientific knowledge and multidisciplinary expertise in chemistry, bioconjugation, analytics, and translational research enable seamless drug development support from discovery through the clinic, with fast timelines and high-quality outcomes. The company also supports innovation through the development of novel technologies, including a murine model for assessing ADC-induced ILD, a plate-based conjugation method, and advanced analytical approaches for conjugate characterization.